Literature DB >> 32299462

Candida infections in severe acute pancreatitis: we need to do more in order to distinguish invasive infection from simple colonization.

Patrick M Honore1, Aude Mugisha2, Luc Kugener2, Sebastien Redant2, Rachid Attou2, Andrea Gallerani2, David De Bels2.   

Abstract

Entities:  

Mesh:

Year:  2020        PMID: 32299462      PMCID: PMC7164234          DOI: 10.1186/s13054-020-02873-y

Source DB:  PubMed          Journal:  Crit Care        ISSN: 1364-8535            Impact factor:   9.097


× No keyword cloud information.
We read with great interest the recent paper regarding anti-infective therapy for severe acute pancreatitis (SAP) by Montravers et al., who conclude regarding fungal infections that most of their cases received azoles in the context of both documented and empirical antifungal therapies [1]. We would like to make some comments. Candida is present in huge quantity in the colon. An increase over the years in Candida infection in non-neutropenic critically ill patients has been demonstrated to put them at increased risk of mortality and morbidity [2]. While there is a concern that this is the case in patients with SAP [3], this has not been universally demonstrated [4]. It is, however, likely that colonization plays an important instigating role in these invasive infections [4]. Patients with SAP are at a particular risk of invasive Candida infections. In a study by Hall and colleagues, both colonization with Candida spp. and a Candida colonization index score (CCIS) > 0.5 were associated with subsequent infection [4]. The CCIS was calculated for each patient as follows: CCIS = ratio of the number of non-blood distinct body sites colonized with Candida spp. to the total number of body sites cultured [4]. A CCIS ≥ 0.5 predicts Candida infection; therefore, patients who had invasive Candida infections and a CCIS ≥ 0.5 were defined as true positives [4]. In their commentary regarding the Hall paper, Montravers et al. themselves concluded that the mistakes of previous decades in the field of bacterial infection should not be repeated; a step-by-step approach is required [5]. Additional scientifically rigorous studies with accurate descriptions of cases similar to those in the article by Hall et al. [4] are required before prophylaxis or extensive therapeutic indications of antifungal agents in SAP can be proposed [5]. In conclusion, we believe that the cohort study of Montravers et al. should have discussed in more detail the importance of distinguishing between invasive Candida infections and colonization, noting, for instance, the utility of scoring systems such as the CCIS score in preventing unnecessary treatment for Candida colonization.
  5 in total

1.  A bedside scoring system ("Candida score") for early antifungal treatment in nonneutropenic critically ill patients with Candida colonization.

Authors:  Cristóbal León; Sergio Ruiz-Santana; Pedro Saavedra; Benito Almirante; Juan Nolla-Salas; Francisco Alvarez-Lerma; José Garnacho-Montero; María Angeles León
Journal:  Crit Care Med       Date:  2006-03       Impact factor: 7.598

2.  Intra-abdominal Candida infection during acute necrotizing pancreatitis has a high prevalence and is associated with increased mortality.

Authors:  A Hoerauf; S Hammer; B Müller-Myhsok; H Rupprecht
Journal:  Crit Care Med       Date:  1998-12       Impact factor: 7.598

3.  Candida and severe acute pancreatitis: we won't be fooled again.

Authors:  Philippe Montravers; Sandrine Boudinet; Hamda Houissa
Journal:  Crit Care       Date:  2013-05-01       Impact factor: 9.097

4.  Epidemiology and prognosis of anti-infective therapy in the ICU setting during acute pancreatitis: a cohort study.

Authors:  Philippe Montravers; Elie Kantor; Jean-Michel Constantin; Jean-Yves Lefrant; Thomas Lescot; Nicolas Nesseler; Catherine Paugam; Matthieu Jabaudon; Hervé Dupont
Journal:  Crit Care       Date:  2019-12-05       Impact factor: 9.097

5.  Prediction of invasive candidal infection in critically ill patients with severe acute pancreatitis.

Authors:  Alison M Hall; Lee A L Poole; Bryan Renton; Alexa Wozniak; Michael Fisher; Timothy Neal; Christopher M Halloran; Trevor Cox; Peter A Hampshire
Journal:  Crit Care       Date:  2013-03-18       Impact factor: 9.097

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.